Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04828304
Other study ID # PULSE study
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date May 26, 2021
Est. completion date December 2024

Study information

Verified date December 2023
Source Plasmacure
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the PULSE study are the followingL A.To perform post market clinical follow up (PMCF) on safety and efficacy: 1. Safety: To confirm transient short-terms side effects and verify long-term/outstanding risks. 2. Efficacy: To confirm the performance of PLASOMA, i.e. the beneficial effect on bacterial load. B. Determine the effect of PLASOMA on wound surface area. A secondary purpose is to examine the beneficial effects of PLASOMA on wound healing and to perform a health technology assessment (HTA). This clinical study will be an open label two-armed randomized controlled trial (RCT), performed at at least three sites (multi-center) in the Netherlands. The two arms are: 1. Control group: Standard wound care for 12 weeks or until healing, whichever occurs first; 2. Treatment group: Standard wound care + PLASOMA treatment for 12 weeks or until healing, whichever occurs first. The frequency of PLASOMA treatment will be determined by the treating (para)medical professional based on the number of visits they would schedule for the standard wound care at the study site. For all study subjects, the treatment frequency will be at least once per week (in order to have enough treatments for safety evaluation) and should not exceed once per day. Follow up (FU) will be performed at three timepoints for both arms: - FU1: 2 weeks after end treatment period - FU2: 12 weeks after end treatment period - FU3: 12 months after start treatment.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 101
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria: INCL1: have a slow-healing or non-healing ulcer consisting of, but not limited to: - diabetic ulcers (Wagner-Meggitt classification system/ University of Texas classification system: grades 1-3) - venous ulcers - pressure ulcers (international NPUAP/EPUAP classification system: categories/stages II-IV) - burn wounds (second and third degree) - skin grafts and flaps - infected post-surgical ulcers. Standard wound care has not resulted in sufficient healing after at least two weeks (including first line care) (Ref 25, Ref 26). Note: There is no upper limit for the duration that the wound exists. In case a subject has multiple wounds that meet the in- and exclusion criteria, the wound with the longest duration will be chosen for the study. INCL2: have a wound with a minimum wound surface area of 0.5 cm2 and a maximum diameter of 4.5 cm (~16 cm2 wound surface area for circular wounds). INCL3: have a minimum age of 18 years old. INCL4: for home care treatments only: have a grounded wall socket available for connection of PLASOMA. Exclusion criteria: EXCL1: the subject has one or more of the following contraindications for PLASOMA: - the wound is very exudative, i.e. wounds in which moisture is visible again within a few minutes after patting dry. - any implanted active electronic device, such as a pacemaker, is present. - an electronic medical device is attached to the body, including electronic life support equipment, hearing aids, glucose sensors and insulin pumps. If the sole purpose of the medical device is monitoring, the subject is not excluded, but it should be noted that use of PLASOMA together with such devices has not been tested and may lead to erroneous operation of the attached device during PLASOMA treatment. - Note: no exclusion if electronic medical device will be detached during PLASOMA treatment. - a metal implant (including a stent) is present in the treatment area, i.e. the area between pad and electrode. - a conductive connection from outside to inside the body at or near the heart is present, e.g. a catheter with electrolyte fluid. - the subject has epilepsy - the subject is pregnant - the to-be-treated wound is located on the torso above the navel EXCL2: the subject has any known malignant wound degeneration. EXCL3: the subject receives treatment with immunosuppressive agents or oral corticosteroids; no exclusion if subject has received a stable dose for at least 2 months and the oral corticosteroid dose does not exceed 7.5 mg/day prednisone or equivalent. EXCL4: the subject is receiving or likely to receive advanced wound therapies - such as negative pressure therapy, hyperbaric oxygen therapy, biologicals (e.g. skin substitutes, growth factors), electrophysical therapy - until FU1 for the to be-treated wound. Advanced wound dressings are not excluded. EXCL5: the subject participates in another study which is likely to compromise the outcome of the PULSE study or the feasibility of the subject fulfilling the PULSE study. EXCL6: the subject is unable to provide consent.

Study Design


Intervention

Device:
PLASOMA
Treatment with cold plasma device

Locations

Country Name City State
Netherlands Groene Hart Ziekenhuis Gouda
Netherlands Alrijne Ziekenhuis Leiderdorp
Netherlands Sint Antonius Ziekenhuis Nieuwegein
Netherlands radboud Universitair Medisch Centrum Nijmegen
Netherlands Expertisecentrum Wondzorg (EcW) Oosterhout
Netherlands Maxima Medisch Centrum (MMC) Veldhoven

Sponsors (3)

Lead Sponsor Collaborator
Plasmacure Diabetes Fonds, Pathology and Medical Microbiology

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety PLASOMA - device related SAEs device related SAEs 12 months
Primary Efficacy PLASOMA - bacterial load reduction - Staphylococcus aureus Reduction in number of S. aureus colonies, using wound swab and quantitative analysis once at week 1 (wound swab directly before and after first PLASOMA treatment)
Primary Efficacy PLASOMA - wound surface area reduction Wound surface area reduction 12 weeks
Secondary Safety PLASOMA - all AEs Safety reporting 12 months
Secondary Safety PLASOMA - wound appearance wound appearance 24 weeks
Secondary Efficacy PLASOMA - Bacterial load reduction Bacterial load reduction (total load and Pseudomonas aeruginosa), using wound swab and semi-quantitative analysis once at week 1 (wound swab directly before and after first PLASOMA treatment)
Secondary Efficacy PLASOMA- wound healing Wound healing - wound surface area reduction - wound volume reduction - time to healing 12 weeks
Secondary Efficacy PLASOMA - Quality of Life Quality of Life, using RAND-36 questionnaire 14 weeks
Secondary Efficacy PLASOMA - Quality of Life Quality of Life, using Wound-QoL questionnaire 14 weeks
Secondary Efficacy PLASOMA - Ulcer recurrence Ulcer recurrence 12 months
Secondary Efficacy PLASOMA - wound infection wound infection (clinical classification) 12 weeks
Secondary Efficacy PLASOMA - wound pain wound pain (0-10 numerical rating scale) 12 weeks
Secondary Health Technology Assessment PLASOMA resource usage PLASOMA 12 weeks
Secondary Patient acceptability Patient acceptability (subjects will be asked if they are happy with the PLASOMA treatment) 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04497805 - Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers Phase 2
Withdrawn NCT03675269 - Adjunctive Hyperbaric Oxygen Therapy (HBOT) for Lower Extermity Diabetic Ulcer: N/A
Completed NCT04624516 - Effect of Self-foot Exercise on the Incidence of Plantar Foot Diabetic Ulcer Recurrence N/A
Not yet recruiting NCT06439667 - VIRTUALLY SUPERVISED TELE-EXERCISE PLATFORM FOR ACCELERATING PLANTAR WOUND HEALING
Recruiting NCT05608187 - Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers Phase 2
Not yet recruiting NCT06437028 - Evaluating the Efficacy of Perinatal Membrane Allografts for the Treatment of Diabetic Foot Ulcers. N/A
Not yet recruiting NCT06278935 - Lifestyle Tailored Offloading for Diabetic Foot Ulcers N/A
Withdrawn NCT05024656 - AmnioExcel® Plus vs SOC in the Management of Diabetic Foot Ulcers N/A
Terminated NCT02202668 - Transcutaneous Raman Spectroscope (TRS) Analyses of Diabetic Foot Ulcers N/A
Terminated NCT01966380 - Proof of Concept (Design Validation) in Patient With Hard to Heal Wounds Such as Pressure Ulcer, Diabetic Foot Ulcer and Leg Ulcer, Leia Phase 2
Completed NCT01951768 - Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection Phase 4
Completed NCT01657474 - Comparative Study of Two Application Regimens of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers N/A
Active, not recruiting NCT00389636 - TheraGauzeā„¢ Alone and Regranex®Gel 0.01% Plus TheraGauzeā„¢ in the Treatment of Wagner Stage I Diabetic Foot Ulcers N/A
Completed NCT01181440 - Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers Phase 3
Enrolling by invitation NCT05888259 - Plantar Pressure Distribution in Diabetic Foot Ulcer N/A
Completed NCT04054804 - Digital Foot Check by Using the D-Foot, a New Software
Not yet recruiting NCT05877378 - Efficacy of PICO Single-use System in Chronic Ulcers N/A
Recruiting NCT06037369 - The Short Message-based Customized Standardized N/A
Completed NCT03312595 - Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU) N/A
Recruiting NCT04564443 - A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot N/A